Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16975433 | 0.88 | ALDH1A1 (0.49) | ALDH1A1GAAMAPTCYP1A2CYP2C9 | |
| SCHEMBL13634224 | 0.80 | POLB (0.49) | ALDH1A1GAAMAPTCYP1A2CYP2C9 | |
| SCHEMBL6154434 | 0.79 | SMN1; SMN2 (0.42) | ALDH1A1MAPTHTTSMN1; SMN2ATM | |
| SCHEMBL16985473 | 0.79 | LMNA (0.36) | ALDH1A1GAAMAPTLMNAMEN1 | |
| SCHEMBL16652870 | 0.76 | MAPK1 (0.49) | ALDH1A1MAPTLMNAHTTSMN1; SMN2 | |
| SCHEMBL16652868 | 0.76 | MAPK1 (0.49) | ALDH1A1MAPTLMNAHTTSMN1; SMN2 | |
| SCHEMBL20555539 | 0.76 | MAPK1 (0.49) | ALDH1A1MAPTLMNAHTTSMN1; SMN2 | |
| SCHEMBL16975306 | 0.76 | ALDH1A1 (0.41) | ALDH1A1GAAMAPTCYP1A2CYP2C9 | |
| SCHEMBL29173477 | 0.75 | SMN1; SMN2 (0.39) | ALDH1A1LMNAHTTSMN1; SMN2ATM | |
| SCHEMBL16975539 | 0.74 | ALDH1A1 (0.43) | ALDH1A1GAAMAPTCYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-04-14 | — | — | US | disclosed |
| EP-3099695-B1 | COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-04-08 | — | — | EP | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| WO-2015113452-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | LRRK2, PARK7, PINK1 | ALDH1A1 4033/4885GAA 85/4885MAPT 9/4885 |
| US-20170015668-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | ALDH1A1 3795/4885GAA 32/4885MAPT 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.